Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
141 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Synovial Sarcoma - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Synovial Sarcoma - Pipeline Review, H2 2016', provides an overview of the Synovial Sarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Synovial Sarcoma - The report reviews pipeline therapeutics for Synovial Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Synovial Sarcoma therapeutics and enlists all their major and minor projects - The report assesses Synovial Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Synovial Sarcoma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Synovial Sarcoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Synovial Sarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Synovial Sarcoma Overview 8 Therapeutics Development 9 Pipeline Products for Synovial Sarcoma - Overview 9 Pipeline Products for Synovial Sarcoma - Comparative Analysis 10 Synovial Sarcoma - Therapeutics under Development by Companies 11 Synovial Sarcoma - Therapeutics under Investigation by Universities/Institutes 12 Synovial Sarcoma - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Synovial Sarcoma - Products under Development by Companies 16 Synovial Sarcoma - Products under Investigation by Universities/Institutes 17 Synovial Sarcoma - Companies Involved in Therapeutics Development 18 Adaptimmune Therapeutics Plc 18 Advenchen Laboratories, LLC 19 EpiZyme, Inc. 20 Immune Design Corp. 21 Immunocore Limited 22 Karyopharm Therapeutics, Inc. 23 Merck & Co., Inc. 24 Millennium Pharmaceuticals Inc 25 Novartis AG 26 OncoTherapy Science, Inc. 27 Pfizer Inc. 28 Takara Bio Inc. 29 Synovial Sarcoma - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 ACXT-3102 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 AL-3818 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 axitinib - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 CMB-305 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 everolimus - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 GSK-3377794 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 OTSA-101 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 pembrolizumab - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Recombinant Protein for Oncology - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 Recombinant Proteins 1 for Oncology - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 sapanisertib - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 selinexor - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 SSTC-104 - Drug Profile 125 Product Description 125 Mechanism Of Action 125 R&D Progress 125 tazemetostat - Drug Profile 126 Product Description 126 Mechanism Of Action 126 R&D Progress 126 TBI-1301 - Drug Profile 133 Product Description 133 Mechanism Of Action 133 R&D Progress 133 Synovial Sarcoma - Discontinued Products 134 Synovial Sarcoma - Product Development Milestones 135 Featured News & Press Releases 135 Feb 22, 2016: The completion of phase I clinical study of the anti-cancer therapeutic antibody 'OTSA101' against synovial sarcoma 135 Dec 30, 2015: Epizyme Announces First Patient Dosed in Global Clinical Program Evaluating Tazemetostat in Genetically Defined Solid Tumors 135 Aug 24, 2015: Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with INI1-Negative Tumors or Synovial Sarcoma 136 Oct 17, 2014: Epizyme Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438) in Models of Synovial Sarcoma 138 Jul 30, 2012: OncoTherapy Science Receives Patent For OTSA101 In Japan And US 139 Oct 16, 2011: OncoTherapy Science's Subsidiary Receives French Approval For Clinical Trial Of OTSA101 139 Appendix 140 Methodology 140 Coverage 140 Secondary Research 140 Primary Research 140 Expert Panel Validation 140 Contact Us 140 Disclaimer 141
List of Tables
Number of Products under Development for Synovial Sarcoma, H2 2016 9 Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Synovial Sarcoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 18 Synovial Sarcoma - Pipeline by Advenchen Laboratories, LLC, H2 2016 19 Synovial Sarcoma - Pipeline by EpiZyme, Inc., H2 2016 20 Synovial Sarcoma - Pipeline by Immune Design Corp., H2 2016 21 Synovial Sarcoma - Pipeline by Immunocore Limited, H2 2016 22 Synovial Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 23 Synovial Sarcoma - Pipeline by Merck & Co., Inc., H2 2016 24 Synovial Sarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 25 Synovial Sarcoma - Pipeline by Novartis AG, H2 2016 26 Synovial Sarcoma - Pipeline by OncoTherapy Science, Inc., H2 2016 27 Synovial Sarcoma - Pipeline by Pfizer Inc., H2 2016 28 Synovial Sarcoma - Pipeline by Takara Bio Inc., H2 2016 29 Assessment by Monotherapy Products, H2 2016 30 Number of Products by Stage and Target, H2 2016 32 Number of Products by Stage and Mechanism of Action, H2 2016 34 Number of Products by Stage and Route of Administration, H2 2016 36 Number of Products by Stage and Molecule Type, H2 2016 38 Synovial Sarcoma - Discontinued Products, H2 2016 134
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
